The DOI matches its Crossref record.
Results of a two‐year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate
Abstract
Objective: To evaluate the efficacy, radiographic changes, and safety of abatacept and methotrexate therapy through 2 years in a long‐term extension of a previously published 1‐year study. Methods: Patients who received placebo during year 1 were switched to abatacept. Patients taking abatacept continued to take it. Efficacy and safety were assessed through 2 years. Results: Of 539 patients enrolled in the initial 1‐year study, 488 completed 1 year of the long‐term extension (2% discontinued for lack of efficacy). At 2 years, patients taking abatacept had maintained their responses on the American College of Rheumatology (ACR) improvement criteria and the Disease Activity Score in 28 joints (DAS28; using the C‐reactive protein [CRP] level), as well as their physical function (according to the Health Assessment Questionnaire [HAQ] disability index [DI]) and health‐related quality of life (HRQOL; assessed with the Short Form 36 [SF‐36] health survey), that were observed at the end of the double‐blind period (year 1 versus year 2 values were 81.9% versus 80.3% for ACR 20% improvement, 25.4% versus 30.9% for a DAS28 [CRP] of <2.6, 71.8% versus 66.8% for the HAQ DI, and 9.7 versus 10.6 and 7.3 versus 7.2, respectively, for the mean change in the physical and mental components summary scores of the SF‐36). In the abatacept group, post hoc analysis demonstrated further inhibition of radiographic progression during year 2 (57% reduction in mean change of total score in year 2 versus year 1; P < 0.0001), and minimal radiographic progression was observed (mean change in total score from baseline was 1.1 and 1.6 at year 1 and 2, respectively). Rates of adverse events (AEs) and severe AEs were consistent throughout the cumulative period. Conclusion: The improvements in signs and symptoms, physical function, and HRQOL observed after 1 year of abatacept treatment were maintained through 2 years of treatment. This durability was accompanied by a safety profile consistent with that in the double‐blind portion of the study. Radiographic progression was further inhibited in year 2 compared with year 1, suggesting an increasing effect of abatacept on the inhibition of structural damage in year 2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationWesthovens, R., Robles, M., Ximenes, A. C., Nayiager, S., Wollenhaupt, J., Durez, P., Gomez-Reino, J., Grassi, W., Haraoui, B., Shergy, W., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101121 · Cited by 348
Self-citationLongterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
van VOLLENHOVEN, R. F., EMERY, P., BINGHAM, C. O., KEYSTONE, E. C., FLEISCHMANN, R., FURST, D. E., MACEY, K., SWEETSER, M., KELMAN, A., & RAO, R. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090856 · Cited by 287
Self-citationGenovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon‐Campos, J. A., Porawska, W., Box, J., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30463 · Cited by 196
Self-citation
Metadata
- Authors
- Kremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud‐Mendoza, C., Szechiński, J., Li, T., Teng, J., Becker, J., & Westhovens, R.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2008-03-27
- Volume
- 58
- Issue
- 4
- Pages
- 953-963
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2078595150
- Cited by
- 174
- References
- 0
- FWCI
- 18.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results of a two‐year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. https://app.cochat.ai/papers/10.1002/art.23397
- The paper
- Kremer, J. M., Genant, H. K., Moreland, L. W., Russell, A. S., Emery, P., Abud‐Mendoza, C., Szechiński, J., Li, T., Teng, J., Becker, J., & Westhovens, R. (2008). Results of a two‐year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis & Rheumatism. https://doi.org/10.1002/art.23397
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.